Lipum AB (publ) has signed an agreement with Flerie Invest AB including a loan commitment of SEK 20 million. The agreement which has been signed on market terms, enters into force on 1 June 2024, has a term of 12 months and runs without collateral.

"We are in a very intense phase with the completion of the clinical phase 1 study as well as we intend to start the planning of a phase 2 study. At the same time, we run several preclinical initiatives where we need flexibility in optimizing the execution. With this loan commitment, we get a security to carry out the activities without unnecessary delay. I am very pleased with the support we receive from our major shareholder Flerie Invest ", says Ola Sandborgh, CEO of Lipum.